Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Other Working Capital Changes (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Other Working Capital Changes for 16 consecutive years, with -$7.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Working Capital Changes fell 20.38% year-over-year to -$7.5 million, compared with a TTM value of -$401000.0 through Dec 2025, down 8.67%, and an annual FY2025 reading of -$401000.0, down 8.67% over the prior year.
  • Other Working Capital Changes was -$7.5 million for Q4 2025 at Catalyst Pharmaceuticals, down from $6.7 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $11.1 million in Q2 2024 and bottomed at -$7.5 million in Q4 2025.
  • Average Other Working Capital Changes over 5 years is $278950.0, with a median of -$78500.0 recorded in 2022.
  • Peak annual rise in Other Working Capital Changes hit 6844.3% in 2023, while the deepest fall reached 1729.49% in 2023.
  • Year by year, Other Working Capital Changes stood at $4.8 million in 2021, then plummeted by 101.64% to -$78000.0 in 2022, then tumbled by 1729.49% to -$1.4 million in 2023, then crashed by 335.74% to -$6.2 million in 2024, then dropped by 20.38% to -$7.5 million in 2025.
  • Business Quant data shows Other Working Capital Changes for CPRX at -$7.5 million in Q4 2025, $6.7 million in Q3 2025, and $484000.0 in Q2 2025.